References

1. Mooradian AD, Chehade J, Thurman JE (2002) The role of thiazolidinediones in the treatment of patients with type 2 diabetes mellitus. Treat Endocrinol 1: 13-20. View
2. Farmer JA (2008) Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. Curr Diab Rep 8: 71-77. View
3. Kataokam Y, Uno K, Nicholls SJ (2011) Management of Dyslipidemia in Patients with Diabetes. US Endocrinol 7: 40-45.
4. American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, et al. (2008) Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. Diabetes Care 31 Suppl 1: S61-78. View
5. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421. View
6. Look AHEAD Research Group, Pi-Sunyer X, Blackburn G, Brancati FL, Bray GA, et al. (2007) Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care 30: 1374-1383. View
7. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, et al. (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348: 383-393. View
8. Kim YD, Park KG, Lee YS, Park YY, Kim DK, et al. (2008) Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 57: 306-314. View
9. Rojas LB, Gomes MB (2013) Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr 5: 6. View
10. Save V, Patil N, Moulik N, Rajadhyaksha G (2006) Effect of atorvastatin on type 2 diabetic dyslipidemia. J Cardiovasc Pharmacol Ther 11: 262-270.
11. Diabetes Atorvastin Lipid Intervention (DALI) Study Group (2001) The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebocontrolled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 24: 1335-1341. View
12. Balasubramanian R, Varadharajan S, Kathale A, Nagraj LM, Periyandavar I, et al. (2008) Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. J Indian Med Assoc 106: 464-467. View
13. Jones PH, McKenney JM, Karalis DG, Downey J (2005) Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Am Heart J 149: e1. View
14. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435. View
15. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, et al. (2006) Treating to New Targets Investigators. Effect of lowering LDL-C cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diab Care 29: 1220-226.
16. Bluett J, Morgan C, Thurston L, Plant D,Hyrich KL, et al. (2014) Impact of inadequate adherence on response to subcutaneously administered antitumor necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. Rheumatology (Oxford); 10. pii: keu358.
17. Ho PM, Bryson CL, Rumsfeld JS (2009) Medication adherence: its importance in cardiovascular outcomes. Circulation 119: 3028-3035. View
18. Spencer FA, Fonarow GC, Frederick PD, Wright RS, Every N, et al. (2004) Early withdrawal of statin therapy in patients with non-ST-segment elevation myocardial infarction: national registry of myocardial infarction. Arch Intern Med 164: 2162-2168. View